Journal Mobile Options
Table of Contents
Vol. 33, No. 6, 2010
Issue release date: June 2010
Add to my selection Citation Download
Onkologie 2010;33:321–323
(DOI:10.1159/000313680)
Case Report · Kasuistik

Osteonecrosis of the Jaw after a Single Bisphosphonate Infusion in a Patient with Metastatic Renal Cancer Treated with Sunitinib

Bozas G. · Roy A. · Ramasamy V. · Maraveyas A.
Academic Department of Medical Oncology, Castle Hill Hospital, Cottingham, Hull and East Yorkshire Hospitals NHS Trust, United Kingdom Onkologie 2010;33:321–323 (DOI:10.1159/000313680)

Abstract

Background: Osteonecrosis of the jaw (ONJ) is recognised as an important adverse effect of intravenous bisphosphonates. Recent reports have suggested that antiangiogenic agents may promote the development of this condition. Case Report: We report a case of ONJ occurring within days after the first infusion of zoledronic acid in a patient being treated with sunitinib for metastatic renal cancer. No dental procedure contributed to the occurrence of ONJ. The patient had previously experienced oral mucositis caused by sunitinib. ONJ improved with conventional oral hygiene measures, zoledronic acid discontinuation, and hyperbaric oxygen treatment. Conclusions: Sunitinib-induced mucosal injury and inhibition of angiogenic signalling pathways, also involved in bone repair and remodelling, may have precipitated the phenomenon. A possible synergistic effect may need to be increasingly addressed in the clinical setting since the concomitant use of sunitinib with bisphosphonates is becoming common.

 goto top of outline Author Contacts

George Bozas, MD, Queen’s Oncology Centre, Casltle Hill Hospital, Cottingham HU16 5JQ, Hull and East Yorkshire Hospitals Trust, UK, Tel. +44 1482-875875, Fax -607739, geothb@yahoo.gr, georgios.bozas@hey.nhs.uk


 goto top of outline Article Information

Published online: May 11, 2010
Number of Print Pages : 3


 goto top of outline Publication Details

Onkologie (International Journal for Cancer Research and Treatment)

Vol. 33, No. 6, Year 2010 (Cover Date: June 2010)

Journal Editor: Schmoll H.-J. (Halle/Saale)
ISSN: 0378-584X (Print), eISSN: 1423-0240 (Online)

For additional information: http://www.karger.com/ONK


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.